Holen Sie sich die Stockscreener-App
13.30
4.59%
-0.6503
Schlusskurs vom Vortag:
$13.95
Offen:
$14.08
24-Stunden-Volumen:
246.11K
Relative Volume:
0.29
Marktkapitalisierung:
$785.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-219.88M
KGV:
-3.5715
EPS:
-3.7238
Netto-Cashflow:
$-175.76M
1W Leistung:
-15.44%
1M Leistung:
+14.84%
6M Leistung:
+103.83%
1J Leistung:
+49.22%
1-Tages-Spanne:
$13.27
$14.28
1-Wochen-Bereich:
$13.27
$16.49
52-Wochen-Spanne:
$5.68
$16.74
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
13.29 | 824.11M | 0 | -219.88M | -175.76M | -3.7238 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.30 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.20 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.47 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.53 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.27 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Eingeleitet | Citigroup | Buy |
| 2026-02-02 | Eingeleitet | Guggenheim | Buy |
| 2025-08-21 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-06-11 | Fortgesetzt | Stifel | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Whale Trades: Can Cullinan Therapeutics Inc outperform under higher oil pricesDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Cullinan Therapeutics (CGEM): Wedbush Raises Price Target to $36 - GuruFocus
CGEM: Key T-cell engager programs advance toward pivotal milestones and data readouts in 2026 - TradingView
Cullinan Therapeutics: Q4 Earnings InsightsCullinan Therapeutics (NASDAQ:CGEM) - Benzinga
Cullinan Oncology (CGEM) Projects Strong Cash Position into 2029 - GuruFocus
Cullinan Therapeutics Reports 2025 Financial Results, Updates on CLN-978, Zipalertinib NDA, and 2026 Clinical Milestones - Minichart
Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings - AlphaStreet
Stifel raises Cullinan Oncology stock price target on autoimmune progress - Investing.com
Cullinan Therapeutics (CGEM) Reports Q4 Loss of $0.77 Per Share, Flat Year-Over-Year - AlphaStreet
Cullinan Therapeutics 2025 10-K: Advancing First-in-Class Therapies for Autoimmune Diseases and Cancer, Risks, and Strategic Developments - Minichart
Cullinan Therapeutics 2025 Financial Report: Q4 Loss Beats EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Cullinan Therapeutics (CGEM) Anticipates Major Developments thro - GuruFocus
Cullinan Therapeutics: Fourth Quarter Earnings Overview - Bitget
Earnings Flash (CGEM) Cullinan Therapeutics Posts Q4 Net Loss $0.77 a Share, vs. FactSet Est of $0.77 Loss - marketscreener.com
Cullinan Therapeutics (NASDAQ:CGEM) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Cullinan Therapeutics 10-K — $0 Revenue, Net Loss $219.9M - TradingView
Cullinan Therapeutics: Q4 Earnings Snapshot - 10TV
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 ... - Bluefield Daily Telegraph
BRIEF-Cullinan Therapeutics Q4 Operating Expenses USD 55.259 Million - TradingView
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
Jennifer Michaelson Sells 8,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference - MarketBeat
Blue Owl Capital Holdings LP Has $14.89 Million Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
What is Cullinan Therapeutics Incs valuation compared to sector2025 Biggest Moves & Precise Buy Zone Tips - baoquankhu1.vn
Can Cullinan Therapeutics Inc generate free cash flowWeekly Stock Recap & Smart Money Movement Tracker - baoquankhu1.vn
[SCHEDULE 13G] Cullinan Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
CGEM: Transformational milestones and pivotal data for autoimmune and AML programs expected by 2026 - TradingView
CGEM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cullinan Therapeutics (CGEM) Stock Analysis: Exploring A 101% Upside Potential - DirectorsTalk Interviews
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 7.6%Here's Why - MarketBeat
Cullinan Therapeutics executives to join major healthcare conference fireside chats - Traders Union
Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $25,169.20 in Stock - MarketBeat
Insider Sell: Jennifer Michaelson Sells Shares of Cullinan Thera - GuruFocus
Cullinan Therapeutics (CGEM) CSO sells 1,780 shares in Rule 10b5-1 trade - Stock Titan
CGEM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 1,752 Shares - MarketBeat
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells 3,601 Shares of Stock - MarketBeat
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $66,301.54 in Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) CEO Nadim Ahmed Sells 13,515 Shares - MarketBeat
Cullinan Therapeutics (CGEM) CSO sells 5,353 shares under 10b5-1 plan - Stock Titan
Cullinan Therapeutics (CGEM) CMO sells shares to cover RSU tax bill - Stock Titan
[Form 4] Cullinan Therapeutics, Inc. Insider Trading Activity - Stock Titan
Jennifer Michaelson sells shares under 10b5-1 (CGEM) - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 12-Month HighWhat's Next? - MarketBeat
Cullinan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Cullinan Therapeutics: Thesis Strengthening For T-Cell Engager Specialist (NASDAQ:CGEM) - Seeking Alpha
Jennifer Michaelson Sells 11,742 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jeffrey Alan Jones Sells 4,982 Shares - MarketBeat
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) CFO Sells 4,398 Shares of Stock - MarketBeat
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):